中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 37 Issue 4
Apr.  2021
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(4): 829-833

Change in the activity of glucosylceramide synthase in human hepatoma cell line with hepatitis B virus infection in vitro

DOI: 10.3969/j.issn.1001-5256.2021.04.021
  • 1.

    The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

  • 2.

    Department of Infectious Diseases, The First Hospital of Lanzhou University, Lanzhou 730000, China

  • 3.

    The 12 th Clinical Medical College of Capital Medical University, Beijing 100000, China

  • Received Date: 2020-09-15
  • Accepted Date: 2020-10-21
  • Published Date: 2021-04-20
    Abstract
  •   Objective  To investigate the change in the activity of glucosylceramide synthase, the key enzyme in glycosphingolipid metabolism and synthesis, in Huh7 cells infected by hepatitis B virus (HBV) in vitro.  Methods  Blood samples were collected from nine previously untreated patients with acute hepatitis B who attended Department of Infectious Diseases, The First Hospital of Lanzhou University, from June to August, 2019, and the blood samples collected from seven healthy individuals who underwent physical examination were established as control. Huh7 cells were inoculated with the high-copy HBV particles (> 9.9×107 IU/ml) in the serum of patients with HBV infection (infection group), and Huh7 cells co-cultured with the serum of healthy individuals were established as control group. The expression levels of HBsAg and HBV DNA in the cytoplasm of HBV-infected Huh7 cells were measured, and the correlation between GCS activity and virus was analyzed. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups, and a Pearson correlation analysis was performed.  Results  Compared with the control group, the infection group had a significant reduction in the number of cells, an increase in cell volume, and cell membrane fragmentation. The infection group had a significant increase in the expression of HBsAg in cytoplasm at 4 hours, 8 hours, 2 days, and 5 days after infection (P < 0.05); the expression level of HBV DNA tended to increase significantly from 4 hours after infection to 8 hours, 2 days, and 5 days after infection (16.67±11.55 IU/ml vs 112.01±25.94 IU/ml/328.01±103.50 IU/ml/101.60±49.84 IU/ml, P < 0.001), with the highest level at 2 days after infection. During HBV infection, the activity of GCS gradually increased with the increase in viral replication from 4 hours after infection (126.21±9.59 IU/ml) and reached a peak at 2 days after infection (226.53±36.27 IU/ml), with a significant difference between the infection group and the control group at 2 days after infection (226.53±36.27 IU/ml vs 136.50±15.44 IU/ml, t=3.956, P=0.016 7). The activity of GCS was positively correlated with HBV DNA level (r=0.576 8, P=0.047 1).  Conclusion  Huh7 cells are successfully infected with the high-copy HBV particles in the serum of patients with HBV infection, which mimics the characteristics of HBV infection in vitro to a certain degree. The activity of GCS may be associated with HBV infection, suggesting that glycosphingolipid synthesis and metabolism may be closely associated with HBV.

     

    • FullText(HTML)
    • References(20)
  • [1]
    OMATA M, KANDA T, WEI L, et al. APASL consensus statements and recommendation on treatment of hepatitis C[J]. Hepatol Int, 2016, 10(5): 702-726. DOI: 10.1007/s12072-016-9717-6.
    [2]
    XU ZH, LIU Y, XU DP. Advances in novel anti-HBV agents acting on different targets[J]. Infect Dis Info, 2015, 28(5): 257- 261, 283. DOI: 10.3969/j.issn.1007-8134.2015.05.001.

    许智慧, 刘妍, 徐东平. 针对不同靶点的抗HBV新药研究进展[J]. 传染病信息, 2015, 28(5): 257-261, 283. DOI: 10.3969/j.issn.1007-8134.2015.05.001.
    [3]
    de MARTEL C, GEORGES D, BRAY F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8(2): e180-e190. DOI: 10.1016/S2214-109X(19)30488-7.
    [4]
    SU Y, ZHU YF, TIAN QY, et al. In vitro cell model and mouse model of HBV cccDNA[J]. J Clin Hepatol, 2019, 35(6): 1205- 1211. DOI: 10.3969/j.issn.1001-5256.2019.06.007.

    苏瑜, 朱园飞, 田青右, 等. HBV cccDNA的体外细胞模型和实验小鼠模型[J]. 临床肝胆病杂志, 2019, 35(6): 1205-1211. DOI: 10.3969/j.issn.1001-5256.2019.06.007.
    [5]
    NOORDEEN F, SCOUGALL CA, GROSSE A, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection[J]. PLoS One, 2015, 10(11): e0140909. DOI: 10.1371/journal.pone.0140909.
    [6]
    FLETCHER SP, CHIN DJ, GRUENBAUM L, et al. Intrahepatic transcriptional signature associated with response to interferon-α treatment in the woodchuck model of chronic hepatitis B[J]. PLoS Pathog, 2015, 11(9): e1005103. DOI: 10.1371/journal.ppat.1005103.
    [7]
    NI Y, LEMPP FA, MEHRLE S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J]. Gastroenterology, 2014, 146(4): 1070-1083. DOI: 10.1053/j.gastro.2013.12.024.
    [8]
    HANNUN YA, OBEID LM. Sphingolipids and their metabolism in physiology and disease[J]. Nat Rev Mol Cell Biol, 2018, 19(3): 175-191. DOI: 10.1038/nrm.2017.107.
    [9]
    LIU YY, HILL RA, LI YT. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance[J]. Adv Cancer Res, 2013, 117: 59-89. DOI: 10.1016/B978-0-12-394274-6.00003-0.
    [10]
    LI JF, ZHENG SJ, LIU S, et al. Impact of UGCG siRNA on 7702 hepatocyte proliferation in vitro[J]. J Pract Hepatol, 2018, 21(5): 697-700. DOI: 10.3969/j.issn.1672-5069.2018.05.011.

    李俊峰, 郑素军, 刘霜, 等. 葡萄糖神经酰胺葡萄糖基转移酶siRNA对7702肝细胞增殖的影响及机制研究[J]. 实用肝脏病杂志, 2018, 21(5): 697-700. DOI: 10.3969/j.issn.1672-5069.2018.05.011.
    [11]
    WEGNER MS, GRUBER L, MATTJUS P, et al. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1)[J]. BMC Cancer, 2018, 18(1): 153. DOI: 10.1186/s12885-018-4084-4.
    [12]
    WANG T, WEI J, WANG N, et al. The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244[J]. Biochem Biophys Res Commun, 2015, 456(3): 821-826. DOI: 10.1016/j.bbrc.2014.12.019.
    [13]
    FAVRE D, PETIT MA, TRÉPO C. Latent hepatitis B virus (HBV) infection and HBV DNA integration is associated with further transformation of hepatoma cells in vitro[J]. ALTEX, 2003, 20(3): 131-142.
    [14]
    ZHONG G, YAN H, WANG H, et al. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes[J]. J Virol, 2013, 87(12): 7176-7184. DOI: 10.1128/JVI.03533-12.
    [15]
    CHOI BH, PARK CJ, RHO HM. Insulin activates the hepatitis B virus X gene through the activating protein-1 binding site in HepG2 cells[J]. DNA Cell Biol, 1998, 17(11): 951-956. DOI: 10.1089/dna.1998.17.951.
    [16]
    ZHENG SJ, QU F, LI JF, et al. Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection[J]. Int J Infect Dis, 2015, 33: 149-155. DOI: 10.1016/j.ijid.2015.01.020.
    [17]
    ZHANG JY, QU F, LI JF, et al. Up-regulation of plasma hexosylceramide (d18: 1/18: 1) contributes to genotype 2 virus replication in chronic hepatitis C: A 20-year cohort study[J]. Medicine (Baltimore), 2016, 95(23): e3773. DOI: 10.1097/MD.0000000000003773.
    [18]
    WERR M, PRANGE R. Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles[J]. J Virol, 1998, 72(1): 778-782. DOI: 10.1128/JVI.72.1.778-782.1998.
    [19]
    XU J, ZHAO W, SUN J, et al. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents[J]. J Control Release, 2018, 288: 212-226. DOI: 10.1016/j.jconrel.2018.09.011.
    [20]
    LEVERY SB, MOMANY M, LINDSEY R, et al. Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc: Ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth[J]. FEBS Lett, 2002, 525(1-3): 59-64. DOI: 10.1016/s0014-5793(02)03067-3.
    • Relative Articles

  • Relative Articles

    [1]Hui LIU, Fengmin LU, Jutao GUO. Mechanism of action, clinical research and development, and application prospect of hepatitis B virus core protein allosteric modulators[J]. Journal of Clinical Hepatology, 2022, 38(8): 1726-1732. doi: 10.3969/j.issn.1001-5256.2022.08.005
    [2]Radiology of Infection Sub-branch, Radiology Branch, Chinese Medical Association, Committee on Radiology of Infection, Radiology Branch, Chinese Medical Doctor Association, Radiology Committee on Infectious and Inflammatory Disease, Chinese Research Hospital Association, Radiology of Infection Branch, Working and Treating Committee of HIV/AIDS and STD Association, Radiology of Infectious Disease Management Sub-branch, Infectious Disease Management Branch, Hospital Management Association in China, Beijing Imaging Diagnosis and Treatment Technology Innovation Alliance. Consensus on imaging techniques and diagnostic criteria for hepatitis B virus related early hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(4): 787-791. doi: 10.3969/j.issn.1001-5256.2021.04.013
    [3]Chunxi WANG. The concept of individualized reference values of aminotransferases should be considered in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1028-1028. doi: 10.3969/j.issn.1001-5256.2021.05.010
    [4]Zhou YiHua, Li Tong, Zhuang Hui. Comments on “2019 Chinese practice guideline for the prevention and treatment of hepatitis B virus mother-to-child transmission”[J]. Journal of Clinical Hepatology, 2020, 36(1): 59-61. doi: 10.3969/j.issn.1001-5256.2020.01.013
    [5]Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association, Chinese Society of Perinatal Medicine, Chinese Medical Association. 2020 clinical guidelines on prevention of mother-to-child transmission of hepatitis B virus[J]. Journal of Clinical Hepatology, 2020, 36(7): 1474-1481. doi: 10.3760/cma.j.cn112141-20200213-00101
    [8]Hou YuanPei, Liu ChengYong, Gao YuJin. Affection of the mutations and genotypes of hepatitis B virus precore and basic core promoter on HBeAg expression[J]. Journal of Clinical Hepatology, 2007, 23(4): 251-253.
    [9]Xie Fang, Lin ZunHui, Jin HaiYing, Guo XiangHua, Huang YanXiang, Yin JiMing, Yan Yan, Hao Wa, Niu JingQin, Li Zhuo. The applied value of Dane granule antigen of hepatitis B viral in detecting chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2007, 23(6): 415-417.
    [10]Liu ChengYong, Hou YuanPei, Qian XiuMei, Sun Qing, Song Li. Distribution of hepatitis B virus genotype in Xuzhou and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(3): 151-152.
    [12]Zhu ZhengYan, Du Zhi, Li Tao, Zhang JinJuan, Ma RuiLi. Long-term culture and induce differentiation of hepatic stem cells from human fetal liver in vitro[J]. Journal of Clinical Hepatology, 2004, 20(5): 267-268.
    [16]Zheng JinHui, Wang Feng, Niu JunQi. The cleavage of PreC/C mRNA of HBV in vitro by a 10-23 DNA zyme[J]. Journal of Clinical Hepatology, 2002, 18(6): 334-336.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(0)

    Other cited types(1)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (690) PDF downloads(29) Cited by(1)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2713]YesterdayPV[4302]TodayIP[263]TodayPV[436]Online[35]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return